Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches...
| Հիմնական հեղինակներ: | , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
China Anti-Cancer Association
2023-12-01
|
| Շարք: | Cancer Biology & Medicine |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.cancerbiomed.org/content/20/12/1035 |